Solid Biosciences Inc.
Solid Biosciences is a life sciences company developing gene therapy candidates for rare neuromuscular and cardiac diseases. Its pipeline includes SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for CPVT, SGT-601 for TNNT2-mediated dilated cardiomyopathy, and earlier-stage cardiac candidates. The company also develops platform technologies, including capsid libraries and genetic regulators, and collaborates on cardiac gene therapy research. Solid Biosciences’ candidates are primarily gene transfer products, designed to deliver functional genes to patients’ cells. It aims to develop treatments and license technologies, including its POLARIS-101 capsid, to companies, institutions and academic labs. Its candidates are in various stages of development, and it relies on third-party manufacturers for supply of SGT-003, SGT-212 and SGT-501. Solid Biosciences is headquartered in Charlestown, Massachusetts.
H.C. Wainwright reiterated a Buy rating and $25 price target for Solid Biosciences (SLDB), citing EU orphan designation for its gene therapy SGT-212. The stock is down 9.2% over the past week, trading at $5.81. Analysts have revised earnings upwards, with a consensus Strong Buy rating. The company reported progress in its pipeline and a potential $200M stock offering.
Solid Biosciences (SLDB) received EU orphan designation for SGT-212, a gene therapy for Friedreich’s ataxia. The company reported no serious adverse events in its Phase 1b trial with five participants. Initial data is expected in Q1 2027. SGT-212 also has U.S. Fast Track and Orphan Drug designations.
UBS initiates coverage of Solid Biosciences with a Buy rating and a $20 price target, citing potential upside from its Duchenne Muscular Dystrophy approach and FDA shifts. The stock has seen a 5-day change of $5.465, a 1st Jan change of -6.10%, and a year-to-date change of -20.22%.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning SLDB (Solid Biosciences Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent SLDB coverage spans financial news, regulation and corporate actions.
In the last 30 days, SLDB insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($25K). The most active reporter was Brooks Gabriel, Chief Medical Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The designation reduces development risk and improves commercial potential, likely supporting the stock.
Orphan designation adds regulatory incentives and de‑risking, likely supporting a price increase.
UBS initiates coverage of Solid Biosciences with a Buy rating and a $20 price target, citing potential upside from its Duchenne Muscular Dystrophy approach and FDA shifts. The stock has seen a 5-day change of $5.465, a 1st Jan change of -6.10%, and a year-to-date change of -20.22%.
Analyst upgrade suggests upside potential for SLDB.
Analyst maintains bullish stance with a high price target.
AlphAI scores every news story that mentions SLDB with an AI model for sentiment and relevance, and aggregates insider trades from Solid Biosciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright reiterated a Buy rating and $25 price target for Solid Biosciences (SLDB), citing EU orphan designation for its gene therapy SGT-212. The stock is down 9.2% over the past week, trading at $5.81. Analysts have revised earnings upwards, with a consensus Strong Buy rating. The company reported progress in its pipeline and a potential $200M stock offering.
2 min readSolid Biosciences (SLDB) received EU orphan designation for SGT-212, a gene therapy for Friedreich’s ataxia. The company reported no serious adverse events in its Phase 1b trial with five participants. Initial data is expected in Q1 2027. SGT-212 also has U.S. Fast Track and Orphan Drug designations.
2 min readUBS initiates coverage of Solid Biosciences with a Buy rating and a $20 price target, citing potential upside from its Duchenne Muscular Dystrophy approach and FDA shifts. The stock has seen a 5-day change of $5.465, a 1st Jan change of -6.10%, and a year-to-date change of -20.22%.
1 min readRBC Capital Markets initiated coverage of Solid Biosciences (SLDB) with an Outperform rating and $18 price target, citing potential in Duchenne muscular dystrophy treatment.
1 min readAnalysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.
2 min readSolid Biosciences Inc. (SLDB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001707502 false 0001707502 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
3 min readSolid Biosciences Inc. (SLDB) has received orphan drug designation from the European Commission for SGT-003, its investigational treatment for Duchenne muscular dystrophy. This designation provides significant benefits like market exclusivity in the EU and regulatory assistance, highlighting the company's commitment to rare disease therapies. Despite this positive development, the company holds a low GF Score™ of 39 and has experienced significant insider selling, which investors should consider.
4 min readSolid Biosciences Inc. sponsored the SADS Foundation's Challenging Cases in Inherited Arrhythmias Symposium, demonstrating its commitment to genetic heart rhythm research. This participation aligns with the company's broader focus on advancing precision gene therapy and initiating human trials for conditions like Friedreich ataxia. Solid Biosciences continues to emphasize genetic approaches for treating inherited disorders.
2 min readGuggenheim has initiated coverage on Solid Biosciences (SLDB) with a Buy rating, projecting a potential FDA approval for its lead therapy, SGT-003, for Duchenne muscular dystrophy. Analyst Debjit Chattopadhyay set a price target of $26 per share, noting that while the company faces financial challenges and insider selling, its strong liquidity and high institutional ownership are positives. The biotechnology firm's valuation shows a high P/B ratio, and it carries inherent risks associated with regulatory challenges and high drug development costs.
3 min readSolid Biosciences (SLDB) announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. The data showed robust microdystrophin expression, improved muscle integrity biomarkers, and stabilization/improvement in cardiac function. The company has also reached an agreement with the FDA for its Phase 3 IMPACT DUCHENNE trial, with screening ongoing and first dosing expected in Q1 2026.
3 min read
